Targeting CLL-1 for acute myeloid leukemia therapy

Despite major scientific discoveries and novel therapies over the past four decades, the treatment outcomes of acute myeloid leukemia (AML), especially in the adult patient population remain dismal. In the past few years, an increasing number of targets such as CD33, CD123, CLL-1, CD47, CD70, and TI...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Hongbing, Padmanabhan, Iyer Swaminathan, Parmar, Simrit, Gong, Yuping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480870/
https://www.ncbi.nlm.nih.gov/pubmed/31014360
http://dx.doi.org/10.1186/s13045-019-0726-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480870/
https://www.ncbi.nlm.nih.gov/pubmed/31014360
http://dx.doi.org/10.1186/s13045-019-0726-5

Ejemplares similares